Simufilam
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatic Insufficiency
Conditions
Hepatic Insufficiency
Trial Timeline
Jun 26, 2024 → Dec 7, 2024
NCT ID
NCT06390410About Simufilam
Simufilam is a phase 1 stage product being developed by Cassava Sciences for Hepatic Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT06390410. Target conditions include Hepatic Insufficiency.
What happened to similar drugs?
3 of 18 similar drugs in Hepatic Insufficiency were approved
Approved (3) Terminated (5) Active (12)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06390410 | Phase 1 | Completed |
| NCT06195319 | Phase 1 | Completed |
| NCT05575076 | Phase 3 | Terminated |
| NCT05352763 | Phase 2 | Terminated |
| NCT04932655 | Phase 1 | Completed |
Competing Products
20 competing products in Hepatic Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ITF2357 | Biotrial | Phase 1 | 19 |
| GB1211 + Placebo | Comac Medical | Phase 1/2 | 18 |
| ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) | Idorsia | Phase 1 | 23 |
| Olomorasib | Eli Lilly | Phase 1 | 29 |
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| DS-3201b | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 36 |
| Pexidartinib | Daiichi Sankyo | Phase 1 | 29 |
| Tivantinib + Tivantinib + Tivantinib + Tivantinib | Daiichi Sankyo | Phase 1 | 29 |
| Bocidelpar | Astellas Pharma | Phase 1 | 29 |
| fezolinetant | Astellas Pharma | Phase 1 | 29 |
| enzalutamide | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP2215 | Astellas Pharma | Phase 1 | 29 |
| BPN14770 | Shionogi | Phase 1 | 29 |
| S-217622 | Shionogi | Phase 1 | 29 |
| Lemborexant | Eisai | Phase 1 | 29 |
| Lenvatinib | Eisai | Phase 1 | 29 |